Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Women's Cancers

Trial Profile

Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Women's Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Durvalumab (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Oct 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 19 May 2017 Planned primary completion date changed from 1 May 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top